Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells

CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that impact toxicity and efficacy have been difficult to define because of differences in lymphodepletion regimens and heterogeneity of CAR-T cells administered to individual pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Transl Med
Autors principals: Turtle, Cameron J., Hanafi, Laïla-Aïcha, Berger, Carolina, Hudecek, Michael, Pender, Barbara, Robinson, Emily, Hawkins, Reed, Chaney, Colette, Cherian, Sindhu, Chen, Xueyan, Soma, Lorinda, Wood, Brent, Li, Daniel, Heimfeld, Shelly, Riddell, Stanley R., Maloney, David G.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5045301/
https://ncbi.nlm.nih.gov/pubmed/27605551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaf8621
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars